DiscoverDecera Clinical Education Oncology Podcast
Decera Clinical Education Oncology Podcast
Claim Ownership

Decera Clinical Education Oncology Podcast

Author: Decera Clinical Education

Subscribed: 97Played: 2,549
Share

Description

Updates on new data and best practices in the care of patients with cancer across a wide variety of solid tumors and hematologic malignancies from Decera Clinical Education. Gain practical clinical insights and strategies and earn CME/CE credit for selected episodes.
277 Episodes
Reverse
In this podcast episode, Craig Horbinski, MD, PhD, and Michael W. Ruff, MD, discuss the evolving diagnosis and management of H3 K27–altered diffuse midline glioma (DMG), emphasizing the importance of molecular testing, multidisciplinary collaboration, and emerging therapeutic strategies, including:The molecular and epigenetic characteristics of H3 K27–altered DMG and their implications for tumor classification and diagnosisChallenges in distinguishing DMG from other brainstem lesions and the importance of tissue biopsy, molecular profiling, and integrated pathology reportingEmerging diagnostic approaches, including cerebrospinal fluid analysis, cell-free DNA testing, and epigenomic profilingCurrent treatment strategies and emerging therapies, including radiotherapy, dordaviprone, and investigational CAR T-cell therapiesThe role of tissue stewardship, multidisciplinary coordination, and postmortem research in advancing diagnosis, selecting treatment, and understanding therapeutic responseGet access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify.Presenters:Craig Horbinski, MD, PhDChairProfessor and Clinician Investigator of PathologyDepartment of Laboratory Medicine and PathologyMayo Clinic FloridaVice Chair, Translational Research, Neuro-Oncology CommitteeAlliance for Clinical Trials in OncologyJacksonville, FloridaMichael W. Ruff, MDAssistant Professor of Neurology and Medical OncologyMayo ClinicRochester, MinnesotaLink to full program:https://bit.ly/4iPzgQh Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
In this podcast episode, Toby A. Eyre, MD, MBChB, and Tycel J. Phillips, MD, FASCO, discuss the evolving treatment landscape of R/R mantle cell lymphoma as covalent BTK inhibitor use further expands into the first-line setting. They highlight the similarities and differences between small molecules pirtobrutinib and sonrotoclax including patient selection, step-up dosing requirements, TLS monitoring, efficacy post covalent BTKi, sequencing, and the feasibility of implementing treatment in community practices. They also examine the dosing, efficacy, and safety of CAR T-cell therapy and bispecific antibodies, establishing their current and possible future roles in R/R MCL.Presenters:Toby A. Eyre, MD, MBChBHematology ConsultantDepartment of HematologyOxford University Hospitals NHS TrustOxford, United KingdomTycel J. Phillips, MD, FASCOAssociate Professor of MedicineCity of Hope National Medical CenterDuarte, CaliforniaLink to full program: https://bit.ly/4k7VkrvGet access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
This podcast explores the evolving treatment landscape for marginal zone lymphoma (MZL), focusing on individualized treatment selection, emerging cellular therapies, and novel T-cell–engaging approaches for relapsed/refractory disease. Examine evidence supporting current treatment options, including BTK inhibitors and CAR T-cell therapy, as well as emerging clinical data on CD20 x CD3 bispecific antibodies such as odronextamab and mosunetuzumab. The discussion also addresses clinical trial referral, patient eligibility, and practical strategies for monitoring and managing treatment-related toxicities.Presenters:Dai Chihara, MD, PhDAssociate ProfessorDepartment of Lymphoma and MyelomaUniversity of Texas MD Anderson Cancer CenterHouston, TexasJ.C. Villasboas B., MDAssistant Professor of Medicine and OncologyMayo Clinic College of MedicineConsultant, Division of Hematology, Lymphoma/Bone Marrow Transplant/Cellular Therapy GroupsDirector, Mayo Clinic Immune Monitoring Core LaboratoryRochester, MinnesotaLink to the full program:https://bit.ly/4zw8VOqGet access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
In this podcast episode, Christine M. Bestvina, MD, and Joshua E. Reuss, MD, discuss the current and emerging role of TROP2-directed ADCs in NSCLC, including:Current clinical use of Dato-DXd in previously treated EGFR-mutated NSCLC, including evidence from TROPION-Lung01 and TROPION-Lung05 and considerations for treatment sequencingEmerging efficacy data for investigational TROP2 ADCs, including sacituzumab tirumotecan, and the potential role of these agents in earlier lines of therapyOngoing clinical trials evaluating TROP2 ADCs alone and in combination with immunotherapy, chemotherapy, or EGFR-targeted therapies, including TROPION-Lung07, TROPION-Lung08, TROPION-Lung14, TROPION-Lung15, and AVANZARBiomarker-guided patient selection, including the potential of the TROP2 QCS-NMR biomarker to identify patients most likely to benefit from Dato-DXdSafety and supportive care considerations, including prevention and management of stomatitis, ocular toxicities, and interstitial lung disease/pneumonitisGet access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify.Presenters:Christine M. Bestvina, MDAssociate Professor of MedicineSection of Hematology/OncologyDivision of MedicineUniversity of Chicago MedicineChicago, IllinoisJoshua E. Reuss, MDThoracic Medical OncologistDirector of Thoracic Clinical ResearchAssociate Professor of MedicineGeorgetown Lombardi Comprehensive Cancer CenterWashington, DCLink to full program: https://bit.ly/4iumiap Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
In this podcast episode, Jesus G. Berdeja, MD, and Ajai Chari, MD, discuss evolving therapy in newly diagnosed multiple myeloma, including:Selecting quadruplet therapyOptimal use of bortezomibThe role of autologous stem cell transplantation in the quadruplet eraUse of MRD status to inform treatment decisionsMaintenance strategies Presenters:Jesus G. Berdeja, MDDirector of Myeloma ResearchGreco-Hainsworth Centers for Research PartnerTennessee OncologyNashville, TennesseeAjai Chari, MDProfessor of Clinical MedicineDirector of Multiple Myeloma ProgramUCSF Helen Diller Family Comprehensive Cancer CenterUniversity of California, San Francisco (UCSF) Medical CenterSan Francisco, CaliforniaContent based on an online CME program supported by an educational grant from GSK.Link to full program: https://bit.ly/4yTeLZDGet access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
loading
Comments